IDH2 and acute myeloid leukemia: In a confirmatory open label, randomized phase 3 trial comparing ENA (N = 158) to conventional care regimens (CCR; azacitidine [N = 69], low-dose cytarabine [N = 37], intermediate-dose cytarabine [N = 33], or best supportive care only [N = 22]) in patients with IDH2-mutated R/R-AML, no significant difference in OS was observed with ENA vs. CCR (median OS 6.5 vs. 6.2 months, HR: 0.86 [95% CI: 0.7–1.10], p-value: 0.23), although a 12% difference in 12-month OS was observed in favor of the ENA arm [61].